A detailed history of Marshall Wace, LLP transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 23,646 shares of SCPH stock, worth $79,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,646
Holding current value
$79,923
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.12 - $5.51 $97,421 - $130,289
23,646 New
23,646 $107,000
Q4 2023

Feb 14, 2024

BUY
$4.7 - $6.63 $161,534 - $227,866
34,369 New
34,369 $215,000
Q1 2023

May 15, 2023

SELL
$5.59 - $9.47 $337,199 - $571,249
-60,322 Reduced 53.52%
52,380 $475,000
Q4 2022

Feb 14, 2023

BUY
$4.02 - $7.53 $453,062 - $848,646
112,702 New
112,702 $808,000

Others Institutions Holding SCPH

About scPharmaceuticals Inc.


  • Ticker SCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,402,100
  • Market Cap $92.6M
  • Description
  • scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...
More about SCPH
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.